Psychedelics on the cusp of market breakthrough as clinical, policy support grow https://www.biospace.com/drug-devel...-breakthrough-as-clinical-policy-support-grow
All eyes on psychedelic drugmakers as Definium, Compass near major catalysts https://www.biospace.com/drug-devel...kers-as-definium-compass-near-major-catalysts
Definium’s LSD asset beats analyst expectations in Phase 3 anxiety readout https://www.biospace.com/drug-devel...alyst-expectations-in-phase-3-anxiety-readout
DT120 (Lysergide) Shows Rapid, Lasting Relief for Generalized Anxiety in Phase 3 Trial https://www.psychiatrictimes.com/vi...lief-for-generalized-anxiety-in-phase-3-trial DT120 (lysergide) hits all endpoints in phase 3 GAD trial, cutting anxiety scores with a single dose.
Psychedelics developer Definium scores more positive data for LSD pill https://www.biopharmadive.com/news/definium-lsd-psychedelics-trial-results-gad-anxiety/827669/ Results from a late-stage study focused on generalized anxiety disorder were a “clean win” to analysts, who believe Definium has a drug with multibillion-dollar sales potential.
Definium says LSD-based pill reduces anxiety in late-stage study https://www.reuters.com/business/he...-reduces-anxiety-late-stage-study-2026-08-12/ Aug 12 (Reuters) - Definium Therapeutics' (DFTX.O), opens new tab LSD-based experimental pill exceeded investor expectations by significantly reducing anxiety symptoms in a late-stage study, meeting the trial's main goal, the company said on Wednesday.
After today’s positive Phase 3 VOYAGE results in GAD, I think the risk profile around DT120 has changed substantially. We now have two successful Phase 3 trials using the same 100 µg dose across two major psychiatric indications, MDD and GAD. Both produced highly significant efficacy, rapid onset and durable benefit, without a new safety signal that materially changes the thesis. At this point, the question of whether pharmaceutical LSD can produce a meaningful therapeutic effect in a rigorous Phase 3 setting has been answered much more convincingly. Rob Barrow’s comments on this morning’s call were also important. Management does not appear overly concerned about the September PANORAMA study and its 50 µg arm because they believe the evidence already generated provides a compelling basis for the regulatory package. PANORAMA still matters, particularly as another GAD replication and because its active-control design addresses some of the questions around functional unblinding, but it no longer feels like an existential test of whether DT120 works. A second positive GAD Phase 3 would strengthen an already convincing efficacy story rather than create it from scratch. There are still regulatory questions around the total safety database, labeling, supervised administration, controlled-substance requirements and ultimately how a several-hour treatment session is implemented commercially. PANORAMA and the remaining MDD program also matter. But those are very different risks from questioning whether the underlying drug has real efficacy. As a long-term holder, that distinction matters to me. I would describe DT120 today as "highly de-risked clinically and substantially de-risked from an approval standpoint", while recognizing that commercial execution remains an important unknown. DFTX has progressed from having an interesting psychedelic candidate to having a drug that has demonstrated Phase 3 efficacy in both depression and anxiety. If PANORAMA is also positive in September, the regulatory case for GAD becomes a lock, but I think the larger shift has already occurred: the debate is increasingly moving away from whether DT120 works and toward how it gets approved, implemented and ultimately commercialized.
LSD Just Passed Its Biggest Trial Yet for Anxiety https://gizmodo.com/lsd-just-passed-its-biggest-trial-yet-for-anxiety-2000797652 It's the second major victory this year for Definium Therapeutics and its proprietary version of LSD.
